CCP
AZN icon

Corient Capital Partners’s AstraZeneca AZN Stock Holding History

Corient Capital Partners’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$923K Buy
6,983
+1,159
+20% +$147K 0.07% 230
2022
Q2 		$770K Sell
5,824
-12,709
-69% -$1.67M 0.06% 262
2022
Q1 		$2.46M Sell
18,533
-1,051
-5% -$126K 0.16% 133
2021
Q4 		$2.28M Sell
19,584
-3,699
-16% -$435K 0.15% 138
2021
Q3 		$2.8M Buy
23,283
+1,789
+8% +$208K 0.2% 108
2021
Q2 		$2.58M Sell
21,494
-19
-0.1% -$2.08K 0.19% 116
2021
Q1 		$2.14M Sell
21,513
-10,226
-32% -$1.03M 0.18% 115
2020
Q4 		$3.17M Buy
31,739
+3,272
+11% +$347K 0.32% 77
2020
Q3 		$3.12M Sell
28,467
-1,077
-4% -$120K 0.36% 67
2020
Q2 		$3.13M Buy
29,544
+2,574
+10% +$266K 0.38% 64
2020
Q1 		$2.41M Buy
26,970
+851
+3% +$80.1K 0.38% 66
2019
Q4 		$2.6M Buy
26,119
+385
+1% +$36.2K 0.33% 70
2019
Q3 		$2.29M Buy
25,734
+3,418
+15% +$296K 0.32% 70
2019
Q2 		$1.84M Buy
22,316
+1,171
+6% +$91.8K 0.28% 86
2019
Q1 		$1.71M Sell
21,145
-1,791
-8% -$141K 0.28% 104
2018
Q4 		$1.74M Sell
22,936
-20,519
-47% -$1.6M 0.31% 94
2018
Q3 		$3.44M Hold
43,455
– – 0.57% 37
2018
Q2 		$3.05M Sell
43,455
-24,913
-36% -$1.79M 0.53% 42
2018
Q1 		$4.78M Sell
68,368
-10,350
-13% -$717K 0.88% 18
2017
Q4 		$5.46M Buy
78,718
+3,221
+4% +$217K 0.93% 20
2017
Q3 		$5.12M Sell
75,497
-7,215
-9% -$456K 0.97% 19
2017
Q2 		$5.64M Sell
82,712
-3,586
-4% -$234K 0.86% 27
2017
Q1 		$5.38M Buy
86,298
+75,398
+692% +$4.39M 0.84% 29
2016
Q4 		$596K Sell
10,900
-55,676
-84% -$3.16M 0.11% 179
2016
Q3 		$4.38M Buy
+66,576
New +$4.35M 0.81% 29

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Corient Capital Partners's AZN Position: Q3 2022 in Review

Corient Capital Partners increased its AstraZeneca (AZN) stake by 20% in Q3 2022, buying an estimated $147K and bringing the position to 6,983 shares worth $923K. The position accounts for 0.07% of the portfolio, ranked #230.

Corient Capital Partners first reported a position in AZN in Q3 2016 and has held it in 25 quarters since. The position peaked at $5.64M in Q2 2017. 965 funds tracked by Wall St. Rank hold AZN as of Q3 2022.

  • Corient Capital Partners held 6,983 shares of AstraZeneca worth $923K as of Q3 2022.
  • Corient Capital Partners bought 1,159 AstraZeneca shares in Q3 2022, an estimated $147K.
  • AstraZeneca made up 0.07% of Corient Capital Partners's portfolio in Q3 2022, its #230 holding.
  • Corient Capital Partners first reported a position in AstraZeneca in Q3 2016 and has held it in 25 quarters since.
  • Corient Capital Partners's AstraZeneca position peaked at $5.64M in Q2 2017.
  • 965 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2022.

Based on Corient Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.